Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695084 · ClinicalTrials.gov registry record · Phase 1
Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)
A Phase 1 study of Multiple Sclerosis, sponsored by National Multiple Sclerosis Society.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00695084 is a Phase 1 study of Multiple Sclerosis that has completed, run by National Multiple Sclerosis Society. The registered enrollment target is 7 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00695084, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by National Multiple Sclerosis Society.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.
Conditions Studied
Interventions
- BEHAVIORAL Constraint-Induced Movement Therapy
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695084
The ClinicalTrials.gov registry entry for NCT00695084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is National Multiple Sclerosis Society, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Constraint-Induced Movement Therapy is the first listed.
NCT00695084 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00695084 about?
NCT00695084 is a clinical study titled "Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)". This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.
What is the current status of trial NCT00695084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2007-03. Estimated completion is 2008-04.
What conditions does trial NCT00695084 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00695084?
The interventions under investigation include: Constraint-Induced Movement Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00695084?
This trial is sponsored by National Multiple Sclerosis Society, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00695084 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.